Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 5/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 5/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 11/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215449 | 0.88 | CYP4F2 (0.47) | CYP4F2CYP4A11RXRARXRBRXRG | |
| Boric Acid SCHEMBL28492132 | 0.84 | CYP4F2 (0.34) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL320082 | 0.81 | CYP4F2 (0.35) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL27630999 | 0.77 | ALDH1A1 (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL25405822 | 0.70 | CYP4F2 (0.45) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29987315 | 0.70 | CYP4F2 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL1649419 | 0.69 | CYP4F2 (0.41) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30739025 | 0.69 | CYP4F2 (0.44) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL2839522 | 0.68 | CYP4F2 (0.42) | CYP4F2CYP4A11ATRALDH1A1LMNA | |
| SCHEMBL5111598 | 0.68 | CD274 (0.40) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2210880-B1 | Benzoxazinone derivatives | MSD KK (JP) | 2015-08-26 | — | — | EP | disclosed |
| US-8314094-B2 | Benzoxazinone derivative | MSD K.K (JP) | 2012-11-20 | — | — | US | disclosed |
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. | 2010-08-19 | — | — | US | disclosed |
| EP-2210880-A1 | BENZOXAZINONE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210636-A1 | BENZOXAZINONE DERIVATIVE | HAX1, CYP4X1, CYP19A1 | CYP4F2 205/4885CYP4A11 50/4885RXRA 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.